Publications & Presentations

Aug 1, 2022

Quantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI: Composite Scores for Longitudinal and Cross-sectional Analysis

Mellion ML, P Widholm, M Karlsson, A Ahlgren, R Tawil, KR Wagner, JM Statland, L Wang, PB Shieh, BGM van Engelen, J Kools, L Ronco, A Odueyungbo, J Jiang, JJ Han, M Hatch, J Towles, O Dahlqvist Leinhard, D Cadavid

Aug 1, 2022

Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole-body fat-referenced MRI: Protocol development, multicenter feasibility, and repeatability

Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole-body fat-referenced MRI: Protocol development, multicenter feasibility, and repeatability Widholm P, A Ahlgren, M Karlsson, T Romu, R Tawil, KR Wagner, JM Statland, LH Wang, PB Shieh, BGM van Engelen, D Cadavid, L Ronco, AO Odueyungbo, JG Jiang, ML Mellion, O Dahlqvist Leinhard Muscle Nerve 2022 Aug 66(2):183-192 doi: 10.1002/mus.27638 https://pubmed.ncbi.nlm.nih.gov/35585766/

Jun 10, 2022

Initial Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Data from an Ongoing Open-Label Study Investigating FTX-6058 in Adults Living with Sickle Cell Disease

Julie Kanter, Jae Ahn, Geoff Allen, Paul Bruno, Judy Dunn, Olga Mitelman, Chris Morabito, Billy Stuart, William Tracewell, John Ziegler

Jun 10, 2022

Inhibition of Polycomb Repressive Complex 2 Through EED Induces Fetal Hemoglobinin Healthy and Sickle Cell Disease Models

Billy Stuart, Paul Bruno, Damon Polioudakis, Mark Roth, Mary Wertz, Alexander Edelstein, Ivan Efremov, David Matson, Judy Dunn

Apr 4, 2022

A phase 2, randomized, double-blind, placebo-controlled, 48-Week study of the efficacy and safety of losmapimodin subjects with FSHD: ReDUX4

Christopher Morabito, MD, CMO

Apr 4, 2022

An Open-Label Study of Losmapimod to Evaluate the Safety, Tolerability, and Biomarker and Clinical Outcome Assessment Changes in Subjects with FSHD1

Joost Kools, Nicol Voermans, Karlien Mul, Lucienne Ronco, John Jiang, Jennifer Shoskes, Kelly Marshall, Diego Cadavid, Michelle L. Mellion, Baziel van Engelen

Apr 4, 2022

Quantitative MuscleAnalysis in FSHD Using Whole-Body MRI: Composite Muscle Measurements for Cross-Sectional Analysis

Per Widholm, Markus Karlsson, André Ahlgren, Olof Dahlqvist-Leinhard, Rabi Tawil, Kathryn Wagner, Jeffrey Statland, Leo Wang, Perry Shieh, Baziel Van Engelen, Diego Cadavid, Lucienne Ronco, Adefowope Odueyungbo, Jay Han, Maya Hatch, Michelle L. Mellion

Apr 4, 2022

Reachable Workspace to Evaluate Efficacy of Losmapimodin Subjects with FSHD in Two Phase 2 Studies

Rabi Tawil, MD, Kathryn Wagner, MD, PhD, Jeffrey Statland, MD, Leo Wang, MD, PhD, Angela Genge, MD, Sabrina Sacconi, MD, PhD, Hanns Lochmüller, MD, PhD, David Reyes Leiva, MD, Jordi Diaz-Manera, MD, PhD, Nuria Muelas, MD, PhD, Juan J. Vilchez, MD, PhD, Alan Pestronk, MD, Summer Gibson, MD, Namita A. Goyal, MD, Johanna Hamel, MD, Jay Han, MD, Lawrence Hayward, MD, Nicholas Johnson, MD, Samantha LoRusso, MD, Miriam Freimer, MD, Perry B. Shieh, MD, PhD, Sankarasubramoney H. Subramony, MD, Doris Leung MD, PhD, Baziel van Engelen MD, PhD, Joost Kools, MD, John Jiang, PhD, L. Alejandro Rojas, PhD, Anthony Accorsi, PhD,Christopher Morabito, MD, Jennifer Shoskes, PharmD, Michelle L. Mellion, MD (first author)

Apr 4, 2022

Whole Body MRI Quantitative muscle analysis to evaluate Efficacy of Losmapimodin a Phase 2 Placebo-Controlled Study in Subjects with FSHD (ReDUX4): ReDUX4 (NCT04003974)

Rabi Tawil, MD, Kathryn Wagner, MD, PhD, Jeffrey Statland, MD, Leo Wang, MD, PhD, Angela Genge, MD, Sabrina Sacconi, MD, PhD, Hanns Lochmüller, MD, PhD, David Reyes Leiva, MD, Jordi Diaz-Manera, MD, PhD, Jorge Alonso-Perez, MD, Nuria Muelas, MD, PhD, Juan J. Vilchez, MD, PhD, Alan Pestronk, MD, Summer Gibson, MD, Namita A. Goyal, MD, Johanna Hamel, MD, Lawrence Hayward, MD, Nicholas Johnson, MD, Samantha LoRusso, MD, Miriam Freimer, MD, Perry B. Shieh, MD, PhD, Sankarasubramoney H. Subramony, MD, Doris Leung MD, PhD, Baziel van Engelen MD, PhD, Joost Kools, MD, Olof Dahlqvist, Per Widholm, John Jiang, PhD, Adefowope Odueyungbo, PhD, William Tracewell, PhD, Alisa Rahilly, BSc, L. Alejandro Rojas, PhD, Anthony Accorsi, PhD, Steve Mennen, PhD, Lucienne Ronco, PhD, Diego Cadavid, MD, Christopher M. Moxham, PhD, Christopher Morabito, MD, Robert Gould, PhD, Michelle L. Mellion, MD.

Mar 16, 2022

Annualized Rates of Change from A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of Losmapimod in Subjects with FSHD: ReDUX4

Rabi Tawil, MD